Bank of New York Mellon
PHIO icon

Bank of New York Mellon’s Phio Pharmaceuticals PHIO Stock Holding History

Bank of New York Mellon’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Hold
0
– -$6K – 4297
2017
Q2 		– Sell
-1
Closed -$37K – 4283
2017
Q1 		$42K Buy
+1
New +$43.2K ﹤0.01% 4159

Other funds holding PHIO

PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Bank of New York Mellon's PHIO Position: Q3 2017 in Review

Bank of New York Mellon held its Phio Pharmaceuticals (PHIO) position steady in Q3 2017 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4297.

Bank of New York Mellon first reported a position in PHIO in Q1 2017 and has held it in 1 quarter since. The position peaked at $42K in Q1 2017. 3 funds tracked by Wall St. Rank hold PHIO as of Q3 2017.

  • Bank of New York Mellon held 0 shares of Phio Pharmaceuticals worth $0 as of Q3 2017.
  • Bank of New York Mellon left its Phio Pharmaceuticals share count unchanged in Q3 2017.
  • Phio Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q3 2017, its #4297 holding.
  • Bank of New York Mellon first reported a position in Phio Pharmaceuticals in Q1 2017 and has held it in 1 quarter since.
  • Bank of New York Mellon's Phio Pharmaceuticals position peaked at $42K in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q3 2017.

Based on Bank of New York Mellon's 13F filing for Q3 2017, filed 6 Nov 2017.